Here, we build upon previously described methods of engineering Tregs (16, 17, 19–21) and demonstrate successful engineering of bulk CD4+ T cells from patients with T1D to generate a cell product, GNTI-122, that overcomes these major challenges. The gene discussed is CD4; the disease is type 1 diabetes mellitus.